Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study - Concepedia

Concepedia

Publication | Closed Access

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

280

Citations

29

References

2016

Year

Michael W. Konstan, Edward F. McKone, Richard B. Moss, Gautham Marigowda, Simon Tian, David Waltz, Xiaohong Huang, Barry Lubarsky, Jaime Rubin, Stefanie J. Millar,

The Lancet Respiratory Medicine

MedicineF508del-cftr MutationPathologyCombination Lumacaftor

References

	Year	Citations

Page 1